INTRODUCTION
T-cell acute lymphoblastic leukemia (T-ALL) is a malignant disorder of immature T cells, representing 15% of pediatric and 25% of adult ALL cases. Progress in T-ALL therapy has been tremendous in the last decades, with cure rates now reaching about 80% for children and 50% for adults. 1, 2 These advances must, however, be tempered by the toxicities of present therapeutic regimens and the dismal prognosis of relapsed cases. T-ALL is classified into subgroups based upon exclusive genetic alterations and/or deregulated expression of specific transcription factors, including the TAL1/2, LMO1/2, TLX1/3 and HOXA families, associated with distinct stages of differentiation arrest. [3] [4] [5] A number of additional, recurrent mutations are found in tumor suppressor genes such as INK4a and ARF, and in oncogenes such as NOTCH 1 activating mutations, that are found in the majority of T-ALL cases. 6 Besides cell autonomous alterations, stromal-derived signals also contribute to leukemia progression and resistance to treatment. 7 For example, although a subset of T-ALL cases present activating mutations in the interleukin 7 (IL7) receptor alpha chain, leukemic cells from most T-ALL patients respond to IL7 ex vivo and depend upon stromal IL7 production to expand in vivo. [8] [9] [10] Calcineurin (PPP3; referred to as Cn) is an ubiquitously expressed protein phosphatase composed of a catalytic subunit (CnA) and a regulatory subunit (CnB). In somatic tissues, CnA is expressed from two distinct genes (PPP3CA and PPP3CB) while a single gene (PPP3R1) encodes CnB1. Critical effectors of Cn are the Nuclear factor of activated T-cells c1-c4( NFATc1-c4) transcription factor family, and Cn/NFAT signaling is involved in a number of developmental processes. 11, 12 In unstimulated cells, NFAT factors are cytoplasmic and hyperphosphorylated on multiple serine residues in their regulatory domain through the activity of different protein kinases, including CK1 (casein kinase 1), GSK3 (glycogen synthase kinase 3) and (dual-specificity tyrosinephosphorylation regulated kinase) DYRK1/2. Following activation of cell surface receptors coupled to calcium mobilization, Cn becomes activated and induces NFAT dephosphorylation and nuclear translocation. 12 In T-cell development, Cn/NFAT signaling is critical to pre-T-cell receptor (TCR) and TCR-mediated positive selection, 13 and controls a number of other aspects of T-cell biology, including helper T-cell differentiation, antigenic activation and anergy. 12 The critical function of Cn in T-cell activation is underscored by the fact that Cyclosporin A (CsA) and Tacrolimus (FK506), two unrelated Cn inhibitors, are strong immunosuppressants that revolutionized transplant medicine.
We and others previously reported sustained activation of the Cn/NFAT signaling pathway in lymphoma, ALL and in mouse models of these malignancies. [14] [15] [16] [17] Cn appears pro-oncogenic in these pathologies as CsA and FK506 administration has 1 antileukemic effects in T-ALL mouse models, 16 whereas CsA treatment has therapeutic benefit in specific lymphoma subtypes. 18 However, systemic delivery of these compounds is expected to inhibit Cn in other tissues besides leukemic cells, including cells of the supportive stroma. Furthermore, CsA and FK506 are associated with a number of ill-characterized off-target effects 19 that could also contribute to their antileukemic activity. We describe here a Notch 1 (intracellular Notch 1, ICN1)-induced mouse T-ALL model, in which Cn can be conditionally and specifically inactivated in tumor cells and show that Cn is critical to leukemic cells initiating/propagating activity. We also show that Cn gene inactivation strongly cooperates with vincristine treatment to induce T-ALL long-term remission.
MATERIALS AND METHODS

Analysis of T-ALL mouse models
Mice carrying the wild-type ( þ ), floxed (fl) and deleted (D) alleles of CnB1 13 and transgenic lines Rosa-Cre-ER T2(ref 20) were maintained on a C57BL/6 genetic background. ICN1-induced T-ALL were obtained following retroviral-mediated gene transfer into bone marrow (BM) cells of the indicated genotypes using MigR1-ICN1, which encodes the entire ICN1 and GFP (green fluorescent protein) from an internal ribosomal entry sequence (IRES)-GFP complementary DNA cassette, as described. 21 We also used Min-ICN1, a retroviral vector encoding ICN1 and a truncated human nerve growth factor receptor (NGFR) from an IRES-tNGFR cassette. 22 T-ALL of the different genotypes emerged within 4-6 weeks, and leukemic cells (GFP þ or tNGFR þ ) were collected from the BM or spleen for further studies. To study Cn function in T-ALL cells, leukemic cells of the indicated genotypes were intravenously (i.v.) infused into syngeneic mice, conditions that result in the synchronous leukemia engraftment in recipient mice. 16 Engraftment was followed by killing the mice at regular time intervals and measuring % GFP þ (tNGFR þ ) leukemic cells in BM. Cre activation was induced in leukemic cells by administration of Tamoxifen (Tam) (Sigma-Aldrich, St Louis, MO, USA; 1 mg/mouse twice at 24 h interval). Carrier solvent (corn oil) was used as control. Unless otherwise stated, Tam administration was started when leukemic burden reached 5-10% T-ALL cells in BM (usually 7-8 days after leukemic cells infusion). In these conditions, Cremediated loss of Cn activity is experienced by leukemic cells 3 days later (see Results) and a tumor burden of 440% leukemic cell in BM. Cohorts were killed when mice became moribund (usually within 7 days after the start of treatment), and the tumor load was analyzed by flow cytometry, leukemic cells being identified as forward light scatter (FSC) large/GFP #3 leukemic cells transduced with a lentiviral vector encoding a firefly luciferase-IRES-GFP expression cassette. 23 After expansion of sorted cells in MS5 cocultures, 10 6 cells were i.v. infused into syngeneic C57BL/6 mice. Two days later, this cohort was divided in two groups. The first was treated with vincristine (Sigma; dissolved in phosphate-buffered saline and injected at 500 mg/kg intraperitoneally); the second was treated with phosphate buffer saline. Bio-imaging experiments showed that this time schedule resulted in transient remission between days 4-8 in vincristine-treated mice as compared with vehicle-treated mice, followed by relapse. A subset of the animals of each group, as detailed in Figure 7 was treated at days 4 and 5 with Tam (1mg/mouse) or carrier solvent (corn oil). Mice were killed when they reached the terminal stage of the disease and analyzed for tumor load as described above. The same cells were retrovirally transduced with either the MSCV-CnB1-IRES-Cherry or the MSCV-IRES-Cherry (control) vectors and GFP þ Cherry þ sorted cells were amplified in MS5 cocultures before infusion in syngeneic recipient mice, as above.
Mice were maintained under specific pathogen-free conditions in the animal facility of the Institut Curie. All experimental procedures were performed in accordance with the recommendations of the European Community (86/609/EEC) and the French National Committee (87/848) for the care and use of laboratory animals. All animal experiments were carried out under the supervision of JG, who was authorized by the director of the Veterinary Services of the Préfecture de l'Essonne (agreement number 91-7). Samples from diagnostic T-ALL cases were obtained in accordance with the Declaration of Helsinki and National ethics rules and xenogratfted into NOD.Cg-Prkdc(scid)Il2rg(tm1Wjll)/SzJ (NSG) mice, as previously decribed. 24 Cell culture MS5 25 
RESULTS
Cn is required for leukemia-initiating/propagating activity To address whether Cn is required for leukemic cell maintenance in T-ALL, we aimed to genetically inactivate Cn in a series of independent leukemias induced by ICN1, a mouse model that recapitulates most features of human T-ALL. 21, 28, 29 We thus generated mice carrying the ROSA-Cre-ER T2 transgene, 20 which entails Cre activation following Tam administration and different combinations of floxed (fl), null (D) or wild-type ( þ ) alleles of CnB1.
13 CnB1 encodes the regulatory subunit of Cn in somatic tissues and is essential for Cn activity. T-ALLs were generated following the transduction of BM cells from these mice with a retrovirus encoding ICN1 and GFP. GFP þ leukemic cells were next infused into wild-type syngeneic recipient mice, a procedure that results in their synchronous engraftment and restricts Cre- Figure 1) . In contrast, no difference in tumor load was observed between Tam-and solvent-treated mice carrying CnB1 fl/ þ or CnB1 þ / þ leukemias, excluding nonspecific effects of Tam administration or Cre activation. 30 When Tam or carrier solvent were administered at high leukemic burden (see Materials and methods), we observed no effect on tumor load between mice carrying the Cn þ and Cn-version of a series of Table 1 ). In contrast, Cn-deficient leukemic cells failed to propagate leukemia to recipient hosts, which remained disease-free for up to 5 months ( Figure 2a ; Table 1 ). Occasionally, mice infused with CnB1 D/D tumor cells became leukemic with delayed latency (for example, leukemia no. 20, Table 1 ). However, leukemic cells recovered from these recipients were of the original CnB1 fl/D genotype, and were thus reinitiated from a minor population of tumor cells that escaped Cre-mediated excision of the floxed CnB1 allele (Supplementary Figure 3) . Besides, the inability of Cn-deficient leukemic cells to reinitiate leukemia was rescued by prior retroviral-mediated transduction of leukemic cells with an exogenous CnB1 gene (Figures 2b-d) , confirming the specificity of the observed phenotype. Failure of Cn-deficient leukemic cells to reinitiate leukemia may reflect a number of abnormalities, including impaired extravasation/homing to and intravasation from target organs, impaired addressing and lodging to their stromal niche or defective responses to intrinsic and niche-derived signaling cues. Although Cn deficiency results in altered leukemic cell homing (see below), two lines of evidence point to critical post-homing defects. First, when homing is bypassed by direct infusion of leukemic cells into the femoral bone cavity, Cn-deficient leukemic cells still failed to reinitiate the disease, in contrast to their Cn þ counterparts (Figure 2e ; Supplementary Table 2) . As in other systems, [31] [32] [33] ICN1 T-ALL cells reach their stromal niches within hours following their inoculation to recipient mice (see below). We thus infused CnB1 fl/þ , fl/fl or fl/D ICN1 leukemic cells into mice and allowed proper lodging to their niches followed by Tam or carrier solvent administration. Under these conditions, Cn inactivation also abrogated leukemia reinitiation (Figure 2f ; Supplementary Table 3) . Taken together, these independent experimental settings show an essential post-homing function of Cn in T-ALL reinitiation.
Cn activation is under stromal control ex vivo and important to functional interactions between leukemic and stromal cells We next studied how Cn could impact upon the physical and functional interactions between leukemic and stromal cells, using an ex vivo coculture system. ICN1 leukemic cells die within 1-2 days when maintained ex vivo in conventional tissue culture media. 16 In contrast, these cells survived and proliferated when cocultivated with BM-derived stromal MS5 cells and preserved their ability to reinitiate leukemia when infused to syngeneic recipient mice (data not shown). Likewise, T-ALL cells from the diagnostic samples expand ex vivo when cocultivated with MS5 cells expressing the NOTCH Delta-like1 ligand and maintain LIC activity in xenotransplantation experiments. 27 Interestingly, MS5 cells-derived signals induced Cn/NFAT activation in ICN1 leukemic cells. Indeed, while Cn was rapidly inactivated in ICN1 leukemic cells removed from their in vivo environment and maintained in conventional growth medium, it remained active when these cells were cocultivated with MS5 cells, as evidenced by the dephosphorylation and ensuing nuclear translocation of NFAT (Figures 3a and b) . Leukemic cells from human T-ALL diagnostic cases xenografted in NSG mice also showed sustained Cn activation as evidenced by NFAT dephosphorylation (Figure 4a ). Cn activation was rapidly lost in T-ALL cells incubated in absence of supportive stroma but reinduced or maintained in leukemic cells cocultivated with either mouse MS5 or human HS5 BMderived stromal cells (Figures 4b and c) .
We next investigated whether Cn inactivation might impact on the physical and functional interactions between ICN1 leukemic cells and MS5 stromal cells. We first compared Cn þ and Cn-deficient ICN1 leukemic cells for their clonogenic activity on Table 4 , Cn-deficient tumor cells showed a severe clonogenicity defect as compared with their Cn þ version, a property associated with their increased cell death under these coculture conditions (Figure 3c) . Similarly, pharmacological inhibition of Cn in human T-ALL cells grown on MS5/Delta-like1 stromal cells by treatment with either CsA or FK506 or small hairpin RNA-mediated knockdown of CnB1 expression resulted in cell expansion inhibition and cell death (Figures 4d-f) .
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To investigate whether additional phenotypic traits other than cell death were associated with Cn inactivation under MS5 coculture conditions, we sought to suppress the apoptotic phenotype of Cn-deficient T-ALL cells in this system. To this end, ICN1 mouse leukemic cells were transduced with a retrovirus encoding Bcl2, followed by their immediate reinfusion into syngeneic recipient mice. Bcl2 expression did not affect Cn activation in leukemic cells either in vivo or ex vivo (Figure 3a) and conferred an in vivo advantage to serially transplanted Cn þ leukemic cells as compared with cells transduced with the control vector (Supplementary Figure 4) . Importantly, Bcl2 expression efficiently rescued the cell death phenotype of Cn-deficient leukemic cells in MS5 cocultures (Figure 5a ). This recovered survival translated in only partial correction of the clonogenicity defect of these cells (Supplementary Table 4 Figure 5) , although these phenotypic traits were obscured by the rapid cell death seen under these conditions.
Rescued survival fails to correct the engraftment defect of Cn-deficient leukemic cells We next compared Cn þ /Bcl2 and Cn À /Bcl2 ICN1 leukemic cells for their ability to reinitiate leukemia after infusion into syngeneic recipient mice. Unlike Cn þ /Bcl2 leukemic cells, which efficiently propagated leukemia to new hosts, Cn À /Bcl2 leukemic cells failed to engraft (Figure 6b) . To investigate the basis of this difference, we compared the fate over time of the Cn þ and Cn À versions of leukemic cells originating from the same ICN1/Bcl2 leukemia following their intrafemoral infusion into syngeneic recipient mice. As expected, Cn þ /Bcl2 ICN1 leukemic cells rapidly expanded into the injected bone cavity, intravasated into the blood and disseminated to other organs and killed the recipient mice within 8 days (Figure 6c and data not shown). In contrast, Cn À /Bcl2 ICN1 leukemic cells survived, but only transiently expanded in the injected bone to become undetectable by 27 days (Figure 6c ). During this transient expansion in the infused femur, Cn À /Bcl2 ICN1 leukemic cells failed to intravasate and disseminate to the contralateral femur and spleen (Figure 6c ).
Cn inactivation is associated with the deregulation of specific molecular pathways To gain insight into molecular pathways associated with the antileukemic effects of Cn inactivation, we compared the transcriptional profiles of several ICN1 leukemias in their Cn þ and Cn À versions. Hierarchical clustering analysis of deregulated genes identified a robust signature associated with Cn inactivation with a clear segregation of Cn À deficient from Cn þ leukemic cells (Figure 6d) . Interestingly, several of the transcripts upregulated in Cn À deficient leukemic cells included known tumor suppressive genes (for example, CDKN1A), 34 genes involved in thymocyte apoptosis (for example, NR4A1/Nur77) 35, 36 and genes involved in cell adhesion (for example, CDH1) (Supplementary Table 5 ).
Cn inactivation synergises with vincristine treatment to induce long-term survival of ICN1 leukemic mice Current T-ALL therapies are associated with resistance to treatment and relapse, especially in adults.
1,2 Treatment failure is thought to result in part from the fact that conventional debulking therapies spare the LIC compartment. Consistent with this notion, in T-ALL diagnostic samples, the subclones responsible for relapse are often also those responsible for leukemia reinititation in xenotransplantation assays. 37 As Cn is critical to leukemia reinitiation, we analyzed whether Cre-mediated CnB1 inactivation could cooperate with vincristine, a drug commonly used in ALL induction therapy, to prolong host survival. Mice were infused with ICN1; RC T2 , CnB1 fl/fl leukemic cells and the cohort divided into four groups. The first (control) was treated with vehicle, the second was treated with vincristine, the third was treated with Tam to induce Cre-mediated excision of CnB1 and the fourth was subjected to combined CnB1 inactivation and vincristine treatment, as schematized in Figure 7a . Treatment with vincristine alone or Cre-mediated inactivation of CnB1 delayed leukemia recurrence, and significantly prolonged mouse survival (median survival: 14 days for the untreated group; 16 days for the vincristine-treated group; 19 days for the Cn-deficient group), but all the mice ultimately succumbed from leukemia (Figure 7b ). In contrast, combination of vincristine followed by Cre-mediated inactivation of CnB1 resulted in prolonged survival of 8/13 mice for up to 65 days (Figure 7b ), a time period after which the mice were killed and found to be devoid of detectable leukemic cells in the BM, spleen and liver (data not shown). Importantly, genotyping analyses revealed the presence of the CnB1-floxed allele in leukemic cells retrieved from the mice that succumbed in the Vinc þ Tam arm (data not shown). This shows that the fatal leukemias in this arm originated from the outgrowth of rare leukemic cells that escaped Cre-mediated excision of the CnB1-floxed allele, and thus express a functional Cn. In contrast, no such selection was seen in the tumor cells retrieved from the Tam-only treated arm, which were Cn-deficient. The synergy between vincristine treatment and Cre-mediated CnB1 deletion was suppressed by prior retroviral-mediated transduction of leukemic 
DISCUSSION
Our results show that Cn is essential for the ability of T-ALL leukemic cells to long-term propagate the disease in serial transplantation assays. Leukemic propagating/initiating cell (LIC) activity reflects the ability of leukemic cells occupying a suitable niche to activate survival and self-renewal programs resulting from the conjunction of exogenous signals (for example, niche derived) and endogenous signals associated with the genetic/ epigenetic alterations of tumor cells. 38 The inability of Cn-deficient ICN1 leukemic cells to reinitiate leukemia cannot be explained by defective homing to the BM as these cells still failed to propagate the disease when infused in the femoral space of recipient mice. Ex vivo, survival and expansion of mouse ICN1 T-ALL cells (this study) and of leukemic cells from human T-ALL diagnostic samples 27 and the maintenance of LIC activity require coculture of leukemic cells with BM-derived stromal cells. We found that Cn deletion in ICN1 T-ALL cells and Cn inhibition in human T-ALL cells result in leukemic cells death in the MS5 coculture system, implicating Cn in a prosurvival pathway(s) in response to stromal signals. The survival defect of ICN1 Cn-deficient cells seen under these conditions can be alleviated by enforced expression of Bcl2. Bcl2-transduced Cn-deficient leukemic cells also survive when infused in the BM of recipient mice, but are unable to significantly expand (Figure 6c ), indicating that loss of Cn survival function is not sufficient to explain impaired reinitiating activity. Bcl2-mediated suppression of cell death unraveled that, unlike their Cn þ version that are highly motile and proliferative, Cn-deficient ICN1 leukemic cells show increased adhesive properties to MS5 stromal cells, impaired motility and defective proliferation. In vivo, these adhesion/migration defects are likely to result in impaired ability of leukemic cells to reach appropriate niches or to dynamically exchange between different niche compartments, properties that appear to be involved in the balance of quiescence, self-renewal and differentiation of normal hematopoietic stem and progenitor cells. 7, 39, 40 Thus, as a consequence of abnormal or impaired productive interactions with niche components and response to niche-derived signals, the ex vivo defects of Cn-deficient leukemic cells observed in MS5 cocultures translate in vivo into ineffective leukemic cells survival and selfrenewal that ultimately abrogate leukemia reinitiation.
In developing thymocytes and normal T cells, the Cn/NFAT signaling pathway is a major effector of pre-TCR and TCR signaling. 12 Leukemia progression in several mouse T-ALL models, including ICN1-induced T-ALL, depends upon pre-TCR signaling, whereas established leukemias express a TCR. 41, 42 We have shown that TCR signaling is not responsible for sustained Cn activation in ICN1-or TEL-JAK2-induced T-ALL, as NFAT dephosphorylation is maintained when these leukemias are generated in a RAG2-deficient genetic background ( 16 and data not shown). In contrast, Cn activity is rapidly lost when mouse and human T-ALL leukemic cells are removed from their in vivo environment, indicating that the oncogenic pathways intrinsic to these cells are not sufficient and possibly not involved in Cn activation. Cn activation is maintained or reactivated in mouse ICN1 and human T-ALL cells cocultivated with mouse MS5 and human HS5 stromal cells, indicating that Cn activation in leukemic cells is under stromal control. In the simplest scenario, Cn would couple calcium signaling evoked by cell surface receptors expressed by leukemic cells in response to ligand(s) produced by stromal cells to the dephosphorylation of specific substrates, for example, NFAT and other transcriptional regulators. Immunohistochemical and intravital imaging show that AML and B-ALL leukemic cells engraft to specific BM niches. 33, 43, 44 The identity of the stromal cells in the BM and other organs and the nature of the ligands and receptors responsible for the induction of Cn activation in T-ALL cells remain to be determined. Comparison of the global transcriptome of Cn-deficient versus Cn þ ICN1 T-ALL cells shows deregulated expression of genes involved in the control of adhesion, cell cycle progression and cell survival. The relevance of the deregulation of these genes to the different Cn-dependent phenotypes in T-ALL cells is under study.
Cn is also involved in the ability of ICN1 leukemic cells to cross endothelial barriers in response to specific chemotactic signals ex vivo (Figure 5e ; Supplementary Figure 5 ) and in decreased intra and extravasation ability in vivo (Figures 6a and c) . These properties likely contribute to the delayed leukemic dissemination and improved overall survival of diseased mice observed when Cn ablation is induced in ICN1 T-ALL cells during the early, disseminating phase of the disease (Supplementary Figure 1;  Figure 7b ). This indicates that Cn inhibition will likely be of limited therapeutic value in first remission induction therapy in T-ALL patients, which is efficiently achieved by available chemotherapeutic regimens. 1, 2 Recent results show that T-ALL relapse in patients originates from subclones that are often those responsible for leukemia reinitiation in xenotransplanted mice. Our results show that Cn is required for disease reinitiation both in transplantation assays (Table 1; Supplementary Table 2) and from lodged leukemic cells (Figure 2f; Supplementary Table 3 ). Together these data suggest that Cn inactivation might rather be of optimal therapeutic benefit to eradicate leukemic cells that escaped debulking induction protocols and which are responsible for relapse. Our results showing that Cre-mediated inactivation of Cn strongly reinforces the antileukemic properties of vincristine and induces long-term remission of ICN1 T-ALL are consistent with this notion. Available Cn inhibitors appear suboptimal as potential therapeutic agents, as they are associated with a number of toxic side effects 19 and show severe off-target effects in T-ALL cells, as exemplified by the severe proliferation inhibition of Cn-deficient leukemic cells in response to CsA (Supplementary Figure 6) . The design of more specific Cn inhibitors and of inhibitors targeting the molecular pathways acting either upstream or downstream of Cn activation and their inclusion during consolidation therapy should help to achieve durable remission, a still challenging issue in adult T-ALL.
